MADRIGAL PHARMACEUTICALS, INC.

MDGL - CIK 0001157601

Market cap$10.87 B

Rank#898

SEC filings1,184

MADRIGAL PHARMACEUTICALS, INC. trades as MDGL and has a market capitalization of $10.87 B, making it the #898 largest US-listed company by market value. In its fiscal 2025 annual report the company posted revenue of $958.40M, up 432.1% from the prior year and net income of -$288.28M. This page tracks MADRIGAL PHARMACEUTICALS, INC. through 1,184 SEC filings, with financial statements and metrics updated as new reports are filed.

Key metrics

Revenue (latest FY)$958.40MFY 2025

Net income (latest FY)-$288.28MFY 2025

Operating cash flow (latest FY)-$189.55MFY 2025

Total assets (latest FY)$1.26BFY 2025

Net margin-30.1%latest FY

Financial performance

Over the last 13 fiscal years MADRIGAL PHARMACEUTICALS, INC.'s revenue grew from $147.00K to $958.40M, a compound annual growth rate of 96.5%.

MDGL annual revenueView details

Key statistics

Market cap: $10.87 B
Share price (derived)market cap / shares outstanding: $471.32
EPS (diluted)FY 2025: $-10.15
Shares outstandingas of 2026-05-01: 0.02B
Total equityas of 2026-03-31: $543.45M
Return on equity: -53.0%
Long-term debtas of 2026-03-31: $340.33M
Cash & equivalentsas of 2026-03-31: $227.03M

Latest filings

Filing	Type	Filed
Insider sale notice	144	2026-05-22
Insider trade	4	2026-05-22
Insider trade	4	2026-05-18
Insider sale notice	144	2026-05-18
SCHEDULE 13G/A	-	2026-05-15
Quarterly report	10-Q	2026-05-06
Major company event	8-K	2026-05-06
Major company event	8-K	2026-04-28

Browse the full filing history (1,184 filings)

Recent press releases

Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4)2026-05-21
Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4) | Madrigal Pharmaceuticals, Inc.
Madrigal Present NEW Data Companys Mash Program Easl 20262026-05-20
Madrigal to Present New Data from the Company’s MASH Program at EASL 2026 Demonstrating the Effects of Rezdiffra on Markers of Cardiovascular and Portal Hypertension Risk | Madrigal Pharmaceuticals, Inc.
Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4)2026-05-07
Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4) | Madrigal Pharmaceuticals, Inc.
Madrigal Pharmaceuticals Reports First-Quarter 2026 Financial Results and Provides Corporate Updates2026-05-06
Madrigal Pharmaceuticals Reports First-Quarter 2026 Financial Results and Provides Corporate Updates | Madrigal Pharmaceuticals, Inc.
Madrigal Pharmaceuticals to Release First-Quarter 2026 Financial Results and Host Webcast on May 6, 20262026-05-06
Following the announcement, Madrigal’s management will host a live webcast at 8 a.m. Eastern Time to review the Company’s financial and operating results.

Similar companies

The largest companies sharing MADRIGAL PHARMACEUTICALS, INC.'s SEC industry classification (pharmaceutical preparations).

LLYEli Lilly and Company$1.072 T MDGL vs LLY

JNJJohnson & Johnson$573.98 B MDGL vs JNJ

ABBVAbbVie Inc.$399.47 B MDGL vs ABBV

MRKMerck & Co., Inc.$293.16 B MDGL vs MRK

AZNAstraZeneca PLC$286.27 B MDGL vs AZN

Frequently asked questions

What is MADRIGAL PHARMACEUTICALS, INC.'s market cap?

MADRIGAL PHARMACEUTICALS, INC. (MDGL) has a market capitalization of $10.87 B as of 2026-06-10, ranking #898 among US-listed companies.

How much revenue does MADRIGAL PHARMACEUTICALS, INC. make?

MADRIGAL PHARMACEUTICALS, INC. reported revenue of $958.40M for fiscal year 2025, an increase of 432.1% year over year.

Is MADRIGAL PHARMACEUTICALS, INC. profitable?

In its latest fiscal year MADRIGAL PHARMACEUTICALS, INC. reported a net loss of $288.28M.

Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.